Covington's Lam appointed to Cytochroma board
This article was originally published in Scrip
Cytochroma, a speciality pharmaceutical company developing products to treat and prevent the consequences of vitamin D insufficiency and secondary hyperparathyroidism, has appointed Lily Lam to its board of directors. She will replace Dr Cynthia Lavoie of VG Partners and VenGrowth Advanced Life Sciences Fund, which has been acquired by the Covington Fund, a new investor in Cytochroma. Ms Lam is vice-president of investments at Covington Capital.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.